Allogeneic stem cell transplant in relapsed/refractory multiple myeloma
Official title: Studio Real-life Sull'Utilizzo Del Trapianto Allogenico di Cellule Staminali Ematopoietiche in Pazienti Affetti da Mieloma Multiplo Recidivato Refrattario
Run by Università degli Studi 'G. d'Annunzio' Chieti e Pescara · NCT07777406 · Data updated 2026-11-12
This study looks at real-world use of allogeneic hematopoietic stem cell transplantation in adults with relapsed or refractory multiple myeloma to see how patients fare over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Università degli Studi 'G. d'Annunzio' Chieti e Pescara Academic / other |
| Locations | 1 site (Chieti, CH) |
| Status | Recruiting |
| Started | March 24, 2026 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | August 20, 2026 |
| Trial ID | NCT07777406 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with relapsed/refractory multiple myeloma who have undergone allogeneic hematopoietic stem cell transplantation and provided informed consent.
✕Probably not a fit
Patients who have not received an allo-HSCT or who do not meet IMWG criteria may not benefit from the findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter, observational study combining retrospective and prospective data to characterize outcomes after allogeneic hematopoietic stem cell transplantation in relapsed/refractory multiple myeloma. It does not involve an experimental intervention and relies on standard clinical care and chart review. Eligible patients are adults with IMWG-confirmed disease who have undergone allo-HSCT, and data are collected from participating centers. The study aims to describe patient characteristics, safety, and clinical outcomes in a real-world setting.
Why it matters
Potential benefit: If successful, the study could clarify how allo-HSCT performs in relapsed/refractory myeloma and help guide future patient care decisions.
How similar studies have gone: Prior observational work has explored allo-HSCT in myeloma, with mixed outcomes; this study contributes real-world data but remains observational in nature.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients diagnosed with relapsed/refractory multiple myeloma according to IMWG criteria who have undergone allogeneic hematopoietic stem cell transplantation; * Age ≥ 18 years; * Signature of the informed consent form (where possible). Exclusion Criteria: * Patients diagnosed with primary AL amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), indolent multiple myeloma, or primary plasma cell leukemia; * Patients who have not undergone allogeneic hematopoietic stem cell transplantation; * Age \< 18 years.
Where it's running
-
Dipartimento di Medicina e Scienze dell'Invecchiamento, Università degli Studi "G. d'Annunzio" di Chieti - Pescara
Chieti, Ch, Italy Recruiting
Study contacts
- Study coordinator: Carmine Liberatore, MD
- Email: carmine.liberatore@unich.it
- Phone: +390854252853
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
In Vivo BCMA/GPRC5D Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms
A first-in-human, single-center study tests a two-target CAR-T cell therapy given in vivo to see if it is safe and tolerable in adults with relapsed or refractory plasma cell neoplasms.
-
Exercise program in a natural outdoor environment
This study tests whether a six-month outdoor exercise program can improve the health and wellbeing of healthy adults compared to those who don’t exercise.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.